Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravandi, Farhad, Bashey, Asad, Foran, James, Stock, Wendy, Mawad, Raya, Short, Nicholas, Yilmaz, Musa, Kantarjian, Hagop, Odenike, Olatoyosi, Patel, Anand, Garcha, Raman, Ainsworth, William Barrett, Clynes, Raphael, Kanodia, Jitendra, Ding, Ying, Li, Huajiang, Kye, Steve, Mims, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632668/
https://www.ncbi.nlm.nih.gov/pubmed/37647601
http://dx.doi.org/10.1182/bloodadvances.2023010956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632668/
https://www.ncbi.nlm.nih.gov/pubmed/37647601
http://dx.doi.org/10.1182/bloodadvances.2023010956

Ejemplares similares